

Expert Second Opinion: Investigators Discuss the Optimal Management of HER2-Positive Gastrointestinal Cancers — Microlearning Activity 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Hepatotoxicity is strongly associated with administration of zanidatamab.

 - a. True
 - b. False
2. Trastuzumab deruxtecan and zanidatamab are indicated for patients with previously treated HER2-positive advanced biliary tract cancers.

 - a. True
 - b. False
3. Which of the following is the more heterogeneously expressed biomarker in biliary tract cancers?

 - a. HER2
 - b. FGFR fusions
4. For which of the following HER2 immunohistochemistry categories is a FISH test recommended?

 - a. IHC 3+
 - b. IHC 2+
 - c. IHC 1+